ketorolac has been researched along with Breast Cancer in 26 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A single administration of 30 mg of ketorolac tromethamine before surgery does not increase disease-free survival in high risk breast cancer patients." | 9.30 | Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. ( Berliere, M; Bouche, G; Coulie, PG; De Kock, M; Decloedt, J; Dekleermaker, A; Duhoux, FP; Forget, P; Guillaume, JE; Ledent, M; Machiels, JP; Mustin, V; Swinnen, W; van Maanen, A; Vander Essen, L; Verougstraete, JC, 2019) |
| " We sought to determine if the use of intraoperative ketorolac as part of a multimodal ERAS protocol increased the risk of bleeding complications in breast surgery." | 9.30 | Intraoperative Ketorolac Use Does Not Increase the Risk of Bleeding in Breast Surgery. ( Andaz, C; Borgen, P; Flom, P; Fortes, TA; Manasseh, DM; Rojas, KE, 2019) |
| "After accounting for associations with longer operative times, concomitant IBBR, and bilateral procedures, ketorolac administration did not remain an independent risk factor for hematoma formation." | 8.12 | Postoperative Hematomas in the Era of Outpatient Mastectomy: Is Ketorolac Really to Blame? ( Abujbarah, SM; Ahmad, S; Casey, W; Craner, R; Cronin, PA; Jogerst, K; Kosiorek, HE; Pockaj, BA; Rebecca, A, 2022) |
| "In conservative breast cancer surgery, the intraoperative use of NSAIDs (ketorolac or diclofenac) was associated with an improved DFS {hazard ratio (HR)=0." | 7.80 | Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. ( Bentin, C; Berliere, M; Coulie, PG; De Kock, M; Forget, P; Machiels, JP, 2014) |
| "Ketorolac was given at the end of surgery, and meloxicam was prescribed in the postoperative period to all patients in both groups." | 6.82 | Preventive Analgesic Efficacy of Nefopam in Acute and Chronic Pain After Breast Cancer Surgery: A Prospective, Double-Blind, and Randomized Trial. ( Han, JW; Koo, BW; Lim, DJ; Na, HS; Oh, AY; Ryu, JH, 2016) |
| "Triple negative breast cancer may be the ideal group with which to test perioperative ketorolac to prevent early relapses." | 5.38 | NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. ( Baum, M; Dekock, M; Demicheli, R; Forget, P; Gukas, I; Hrushesky, WJ; Pachmann, K; Retsky, M; Rogers, R; Vaidya, JS, 2012) |
| "A single administration of 30 mg of ketorolac tromethamine before surgery does not increase disease-free survival in high risk breast cancer patients." | 5.30 | Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. ( Berliere, M; Bouche, G; Coulie, PG; De Kock, M; Decloedt, J; Dekleermaker, A; Duhoux, FP; Forget, P; Guillaume, JE; Ledent, M; Machiels, JP; Mustin, V; Swinnen, W; van Maanen, A; Vander Essen, L; Verougstraete, JC, 2019) |
| " We sought to determine if the use of intraoperative ketorolac as part of a multimodal ERAS protocol increased the risk of bleeding complications in breast surgery." | 5.30 | Intraoperative Ketorolac Use Does Not Increase the Risk of Bleeding in Breast Surgery. ( Andaz, C; Borgen, P; Flom, P; Fortes, TA; Manasseh, DM; Rojas, KE, 2019) |
| "Focusing on a high-risk group with preoperative inflammation could lead to a clinical trial to test the effect of ketorolac on cancer outcome." | 4.90 | Perspectives in anaesthesia for cancer surgery. ( De Kock, M; Forget, P, 2014) |
| "After accounting for associations with longer operative times, concomitant IBBR, and bilateral procedures, ketorolac administration did not remain an independent risk factor for hematoma formation." | 4.12 | Postoperative Hematomas in the Era of Outpatient Mastectomy: Is Ketorolac Really to Blame? ( Abujbarah, SM; Ahmad, S; Casey, W; Craner, R; Cronin, PA; Jogerst, K; Kosiorek, HE; Pockaj, BA; Rebecca, A, 2022) |
| "In conservative breast cancer surgery, the intraoperative use of NSAIDs (ketorolac or diclofenac) was associated with an improved DFS {hazard ratio (HR)=0." | 3.80 | Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. ( Bentin, C; Berliere, M; Coulie, PG; De Kock, M; Forget, P; Machiels, JP, 2014) |
| "This retrospective analysis suggests that intraoperative administration of ketorolac decreases the risk of breast cancer relapse compared with other analgesícs." | 3.76 | Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. ( Berliere, M; De Kock, M; Forget, P; Legrand, C; Machiels, JP; Nussbaum, B; Vandenhende, J, 2010) |
| "Ketorolac was given at the end of surgery, and meloxicam was prescribed in the postoperative period to all patients in both groups." | 2.82 | Preventive Analgesic Efficacy of Nefopam in Acute and Chronic Pain After Breast Cancer Surgery: A Prospective, Double-Blind, and Randomized Trial. ( Han, JW; Koo, BW; Lim, DJ; Na, HS; Oh, AY; Ryu, JH, 2016) |
| "Ketorolac is a parenteral nonsteroidal antiinflammatory drug (NSAID)." | 2.68 | Comparison of analgesic effect of locally and systemically administered ketorolac in mastectomy patients. ( Bosek, V; Cox, CE, 1996) |
| "Most relapses in breast cancer are in the early category." | 2.49 | Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. ( Baum, M; De Kock, M; Demicheli, R; Forget, P; Gukas, I; Hrushesky, WJ; Retsky, M; Rogers, RA; Sukhatme, V; Vaidya, JS, 2013) |
| "Ketorolac was given to 1549 (45%) of the women, with 922 women (60%) receiving 30 mg and 627 women (40%) receiving 15 mg." | 1.62 | Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. ( Assel, M; McCormick, PJ; Morrow, M; Nelson, JA; Simon, BA; Tokita, HK; Twersky, RS; Van Zee, KJ; Vickers, AJ, 2021) |
| "This may also explain sudden confusion and dementia for the elderly after surgery." | 1.48 | Breast Cancer Relapse, Post-Surgical Confusion, and Dementia in the Elderly: An Unexpected Connection but with the Same Proposed Solution. ( Forget, P; Retsky, MW, 2018) |
| "The intraoperative use of NSAIDs in breast cancer patients (Centre 1) is associated with a reduced recurrence rate (HR = 0." | 1.39 | Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. ( Berliere, M; Canon, JL; Coulie, PG; De Kock, M; Forget, P; Kremer, Y; Legrand, C; Machiels, JP; Poncelet, AJ; Stainier, A; Tombal, B, 2013) |
| "Triple negative breast cancer may be the ideal group with which to test perioperative ketorolac to prevent early relapses." | 1.38 | NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. ( Baum, M; Dekock, M; Demicheli, R; Forget, P; Gukas, I; Hrushesky, WJ; Pachmann, K; Retsky, M; Rogers, R; Vaidya, JS, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 7 (26.92) | 2.80 |
| Authors | Studies |
|---|---|
| Klifto, KM | 1 |
| Elhelali, A | 1 |
| Payne, RM | 1 |
| Cooney, CM | 1 |
| Manahan, MA | 1 |
| Rosson, GD | 1 |
| Abujbarah, SM | 1 |
| Jogerst, K | 1 |
| Kosiorek, HE | 1 |
| Ahmad, S | 1 |
| Cronin, PA | 1 |
| Casey, W | 1 |
| Craner, R | 1 |
| Rebecca, A | 1 |
| Pockaj, BA | 1 |
| Forget, P | 11 |
| Bouche, G | 2 |
| Duhoux, FP | 2 |
| Coulie, PG | 4 |
| Decloedt, J | 1 |
| Dekleermaker, A | 1 |
| Guillaume, JE | 1 |
| Ledent, M | 1 |
| Machiels, JP | 5 |
| Mustin, V | 1 |
| Swinnen, W | 1 |
| van Maanen, A | 2 |
| Vander Essen, L | 1 |
| Verougstraete, JC | 1 |
| De Kock, M | 8 |
| Berliere, M | 6 |
| McCormick, PJ | 3 |
| Assel, M | 2 |
| Van Zee, KJ | 2 |
| Vickers, AJ | 2 |
| Nelson, JA | 2 |
| Morrow, M | 2 |
| Tokita, HK | 2 |
| Simon, BA | 3 |
| Twersky, RS | 2 |
| Li, L | 1 |
| Zhao, X | 1 |
| Xiang, B | 1 |
| Tang, X | 1 |
| Mikhaylov, Y | 1 |
| Weinstein, B | 1 |
| Schrank, TP | 1 |
| Swartz, JD | 1 |
| Ulm, JP | 1 |
| Armstrong, MB | 1 |
| Delaney, KO | 1 |
| Ben-Eliyahu, S | 1 |
| Golan, T | 1 |
| Desmedt, C | 1 |
| Demicheli, R | 3 |
| Fornili, M | 1 |
| Bachir, I | 1 |
| Duca, M | 1 |
| Viglietti, G | 1 |
| Piccart, M | 1 |
| Sotiriou, C | 1 |
| Sosnowski, M | 1 |
| Biganzoli, E | 1 |
| Sosa, PS | 1 |
| Colla-Machado, PE | 1 |
| Cristiano, E | 1 |
| Retsky, MW | 1 |
| Nguyen, BN | 1 |
| Barta, RJ | 1 |
| Stewart, CE | 1 |
| Wheelwright, M | 1 |
| Heinrich, CA | 1 |
| Rojas, KE | 1 |
| Fortes, TA | 1 |
| Flom, P | 1 |
| Manasseh, DM | 1 |
| Andaz, C | 1 |
| Borgen, P | 1 |
| Poncelet, AJ | 1 |
| Tombal, B | 1 |
| Stainier, A | 1 |
| Legrand, C | 2 |
| Canon, JL | 1 |
| Kremer, Y | 1 |
| Retsky, M | 2 |
| Hrushesky, WJ | 2 |
| Gukas, I | 2 |
| Rogers, RA | 1 |
| Baum, M | 2 |
| Sukhatme, V | 1 |
| Vaidya, JS | 2 |
| Bentin, C | 1 |
| Bailard, NS | 1 |
| Flores, RA | 1 |
| Na, HS | 1 |
| Oh, AY | 1 |
| Koo, BW | 1 |
| Lim, DJ | 1 |
| Ryu, JH | 1 |
| Han, JW | 1 |
| Vandenhende, J | 1 |
| Nussbaum, B | 1 |
| Rogers, R | 1 |
| Dekock, M | 1 |
| Pachmann, K | 1 |
| Kausar, F | 1 |
| Davis, MP | 1 |
| Bosek, V | 1 |
| Cox, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.[NCT01806259] | Phase 3 | 203 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 93 |
| NaCl 0.9% 3mL | 105 |
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 80 |
| NaCl 0.9% 3mL | 96 |
3 reviews available for ketorolac and Breast Cancer
| Article | Year |
|---|---|
Perioperative systemic nonsteroidal anti-inflammatory drugs (NSAIDs) in women undergoing breast surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Humans; Ketorolac; Pain, Postoper | 2021 |
Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Computer Simulation; Disease-Free Surviva | 2013 |
Perspectives in anaesthesia for cancer surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Breast Neoplasms; Clinical Trials as Topic; Fem | 2014 |
5 trials available for ketorolac and Breast Cancer
| Article | Year |
|---|---|
Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Breast Neoplasms; | 2019 |
Intraoperative Ketorolac Use Does Not Increase the Risk of Bleeding in Breast Surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasm | 2019 |
Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Humans; Inflammation; Ketorolac; | 2013 |
Preventive Analgesic Efficacy of Nefopam in Acute and Chronic Pain After Breast Cancer Surgery: A Prospective, Double-Blind, and Randomized Trial.
Topics: Acute Pain; Adult; Aged; Analgesics, Non-Narcotic; Axilla; Breast Neoplasms; Chemoradiotherapy, Adju | 2016 |
Comparison of analgesic effect of locally and systemically administered ketorolac in mastectomy patients.
Topics: Administration, Topical; Analgesics, Non-Narcotic; Analysis of Variance; Breast Neoplasms; Double-Bl | 1996 |
18 other studies available for ketorolac and Breast Cancer
| Article | Year |
|---|---|
Postoperative Hematomas in the Era of Outpatient Mastectomy: Is Ketorolac Really to Blame?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Hematoma; Humans; Ketorolac; Mast | 2022 |
Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Humans; Ketor | 2021 |
ASO Author Reflections: We No Longer Give Ketorolac During Mastectomy. Should You?
Topics: Breast Neoplasms; Female; Humans; Ketorolac; Mastectomy; Mastectomy, Subcutaneous; Nipples | 2021 |
Ketorolac following Mastectomy: Is There an Increased Risk of Reoperation?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Humans; Ketorolac; Mastectomy; Re | 2021 |
Reply to: "Ketorolac Following Mastectomy: Is There an Increased Risk of Reoperation?"
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Humans; Ketorolac; Mastectomy; Re | 2021 |
Ketorolac and Hematoma Incidence in Postmastectomy Implant-Based Breast Reconstruction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Implants; Breast Neoplasms; Female; Hematoma; Humans | 2018 |
Harnessing the Perioperative Period to Improve Long-term Cancer Outcomes.
Topics: Body Mass Index; Breast Neoplasms; Humans; Ketorolac; Neoplasm Recurrence, Local; Perioperative Peri | 2018 |
Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
Topics: Adult; Aged; Body Mass Index; Breast Neoplasms; Female; Humans; Intraoperative Care; Ketorolac; Midd | 2018 |
[Pisa syndrome associated with codeine].
Topics: Acetaminophen; Aged; Analgesics; Back Pain; Breast Neoplasms; Carcinoma, Lobular; Codeine; Drug Subs | 2018 |
Breast Cancer Relapse, Post-Surgical Confusion, and Dementia in the Elderly: An Unexpected Connection but with the Same Proposed Solution.
Topics: Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Confusi | 2018 |
Ketorolac for Patients Undergoing Implant-Based Breast Reconstruction: Impact on Hospital Length of Stay and Postoperative Narcotic Use.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Breast Implantation; Breast Implants; Breast N | 2020 |
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Diclofena | 2014 |
Could opioid sparing, rather than a direct non-steroidal anti-inflammatory drug effect, be responsible for improved survival after conservative breast surgery?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Diclofenac; Female; Humans; Intraoperativ | 2015 |
Reply from the authors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Diclofenac; Female; Humans; Intraoperativ | 2015 |
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Analysis of Variance; Anti-Inflammatory Agents, Non-Ste | 2010 |
NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Combined Mod | 2012 |
Ketorolac in neuropathic pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brachial Plexus Neuropathies; Breast Neoplasms; Carcinoma, | 2006 |